New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives with Modified Ring Systems

Therapeutic Drug Monitoring

Volumn 38, Issue 1, 2016, Pages 4-11

  Welter Luedeke, Jessica ^a,b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

designer drugs; Drugs of abuse; metabolism; new psychoactive substances; pharmacology

Indexed keywords

2 METHIOPROPAMINE; 5 (2 AMINOPROPYL)BENZOFURAN; 6 (2 AMINOPROPYL)BENZOFURAN; AMPHETAMINE DERIVATIVE; CAMFETAMINE; CYTOCHROME P450 ISOENZYME; DOPAMINE; N METHYL 5 (2 AMINOPROPYL)BENZOFURAN; N METHYL 6 (2 AMINOPROPYL)BENZOFURAN; NORADRENALIN; PSYCHOTROPIC AGENT; SEROTONIN; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT;

ACUTE TOXICITY; ANXIETY; ARTICLE; CLINICAL PHARMACOLOGY; DEMETHYLATION; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SULFATION; HUMAN; HYPERTENSION; HYPERTHERMIA; INSOMNIA; MEDICINAL CHEMISTRY; MYDRIASIS; NONHUMAN; PRIORITY JOURNAL; TACHYCARDIA; TOXICOKINETICS; AMPHETAMINE-RELATED DISORDERS; CHEMISTRY; PROCEDURES; SUBSTANCE ABUSE;

AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; SUBSTANCE ABUSE DETECTION;

EID: 84955485140     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000240     Document Type: Article

References (58)

1. United Nations Office on Drugs and Crime (UNODC). The Challenge of New Psychoactive Substances. Global SMART Programme. March 2013: 1-122. Available at: http://www.unodc.org/documents/scientific/NPS-2013-SMART.pdf. Accessed September 23, 2015.
2. United Nations Office on Drugs and Crime (UNODC).World Drug Report 2013. Available at: http://www.unodc.org/documents/lpo-brazil//Topics-drugs/WDR/2013/World-Drug-Report-2013.pdf. Accessed September 23, 2015.
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report: Trends and Developments. Published June 2014. Available at: http://www.emcdda.europa.eu/attachements.cfm/att-239505-EN-TDAT15001ENN.pdf. Accessed September 23, 2015.
4. United Nations Office on Drugs and Crime (UNODC). World Drug Rep. 2014. Published June 26, 2014. Available at: http://www.unodc.org/documents/data-and-analysis/WDR2014/World-Drug-Report-2014-web.pdf. Accessed September 23, 2015.
5. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives. Ther Drug Monit. 2002;24:277-289.
6. Maurer HH. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit. 2010;32:544-549.
7. Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Curr Drug Metab. 2005;6:259-274.
8. Meyer MR, Maurer HH. Metabolism of designer drugs of abuse: an updated review. Curr Drug Metab. 2010;11:468-482.
9. Welter J, Kavanagh P, Maurer HH. GC-MS and LC-(high-resolution)-MSn studies on the metabolic fate and detectability of camfetamine in rat urine. Anal Bioanal Chem. 2014;406:3815-3829.
10. Wee S, Anderson KG, Baumann MH, et al. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther. 2005;313:848-854.
11. Rothman RB, Baumann MH. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci. 2006;1074:245-260.
12. Baumann MH, Clark RD, Woolverton WL, et al. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther. 2011; 337:218-225.
13. Kimmel HL, Manvich DF, Blough BE, et al. Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacol Biochem Behav. 2009;94:278-284.
14. Wellman PJ, Davis KW, Clifford PS, et al. Changes in feeding and locomotion induced by amphetamine analogs in rats. Drug Alcohol Depend. 2009;100:234-239.
15. Negus SS, Mello NK, Blough BE, et al. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther. 2007;320:627-636.
16. Marsh DF, Herring DA. The pharmacological activity of the ring methyl substituted phenisopropylamines. J Pharmacol Exp Ther. 1950;100:298-308.
17. Welter J, Meyer MR, Kavanagh P, et al. Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MSn. Anal Bioanal Chem. 2014; 406:1957-1974.
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Europol Joint Report on a New Psychoactive Substance: 4-methylamphetamine. Available at: http://www.emcdda.europa.eu/attachements.cfm/att-191982-EN-TDAS12001ENN.PDF Accessed December 2013.
19. Iversen L, Gibbons S, Treble R, et al. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol. 2013;700:147-151.
20. Lee HM, Wood DM, Hudson S, et al. Acute toxicity associated with analytically confirmed recreational use of methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane). J Med Toxicol. 2014;10:299-302.
21. McIntyre IM, Gary RD, Trochta A, et al. Acute 5-(2-Aminopropyl)Benzofuran (5-APB) intoxication and Fatality: a case report with Postmortem concentrations. J Anal Toxicol. 2015;39:156-159.
22. Adamowicz P, Zuba D, Byrska B. Fatal intoxication with 3-methyl-Nmethylcathinone (3-MMC) and 5-(2-aminopropyl)benzofuran (5-APB). Forensic Sci Int. 2014;245C:126-132.
23. Welter J, Kavanagh P, Meyer MR, et al. Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques. Anal Bioanal Chem. 2015;407: 1371-1388.
24. Chan WL, Wood DM, Hudson S, et al. Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol. 2013;9:278-281.
25. Welter J, Brandt SD, Kavanagh P, et al. Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem. 2015; 407:3457-3470.
26. Cinosi E, Corazza O, Santacroce R, et al. New drugs on the Internet: the case of Camfetamine. Biomed Res Int. 2014;2014:419026.
27. Planeta CS, Aizenstein ML, DeLucia R. Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors. Pharmacol Biochem Behav. 1995;50:35-40.
28. Seyfried CA. Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983;32:2329-2331.
29. DeLucia R, Bernardi MM, Scavone C, et al. On the mechanism of central stimulation action of fencamfamine. Gen Pharmacol. 1984; 15:407-410.
30. Aizenstein ML, Scavone C, Bernardi MM, et al. Comparative biochemical and behavioural effects of fencamfamine and dl-amphetamine in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1983;7:187-194.
31. DeLucia R, Planeta CS, Scavone C, et al. Reduction of food intake by fencamfamine in rats. Gen Pharmacol. 1987;18:21-23.
32. Planeta CS, Scavone C, De LR, et al. Behavioural effects of long-term administration of fencamfamine: neurochemical implications. Gen Pharmacol. 1987;18:347-349.
33. Planeta CS, Aizenstein ML, Scavone C, et al. Behavioral and neurochemical effects of fencamfamine on rats: a chronobiologic approach. Chronobiol Int. 1989;6:313-320.
34. Kuczenski R, Segal DS, AizensteinML. Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci. 1991;11:2703-2712.
35. DeLucia R, Planeta CS, Aizenstein ML, et al. Repeated administration intensifies the reinforcing effect of fencamfamine in rats. Gen Pharmacol. 1997;29:265-267.
36. Westphal F, Schaefer T, Zechlin L, et al. Identification of 4-methylamphetamine in a seized amphetamine mixture. Toxichem Krimtech. 2011;35:306-315.
37. Higgs RA, Glennon RA. Stimulus properties of ring-methyl amphetamine analogs. Pharmacol Biochem Behav. 1990;37:835-837.
38. Blanckaert P, van AJ, Brunt T, et al. 4-Methyl-amphetamine: a health threat for recreational amphetamine users. J Psychopharmacol. 2013;27:817-822.
39. Bal TS, Gutteridge DR, Johnson B, et al. Adverse effects of the use of unusual phenethylamine compounds sold as illicit amphetamine. Med Sci Law. 1989;29:186-188.
40. Law MY, Slawson MH, Moody DE. Selective involvement of cytochrome P450 2D subfamily in in vivo 4-hydroxylation of amphetamine in rat. Drug Metab Dispos. 2000;28:348-353.
41. Davis S, Blakey K, Rands-Trevor K. GC-MS and GC-IRD analysis of 2-, 3-and 4-methylmethamphetamine and 2-, 3-and 4-methylamphetamine. Forensic Sci Int. 2012;220:67-73.
42. Pedersen AJ, Dalsgaard PW, Rode AJ, et al. Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultrahigh-performance liquid chromatography with TOF-MS with dataindependent acquisition. J Sep Sci. 2013;36:2081-2089.
43. Strano-Rossi S, Anzillotti L, Castrignano E, et al. Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, "spice" and stimulants in oral fluid. J Chromatogr A. 2012;1258:37-42.
44. Blicke FF, Burkhalter JH. alpha-Thienylaminoalkanes. J Am Chem Soc. 1942;64:477-480.
45. Welter J, Meyer MR, Wolf E, et al. 2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem. 2013;405:3125-3135.
46. Casale JF, Hays PA. Methiopropamine: an analytical profile. Microgram J. 2011;8:53-57.
47. Angelov D, O'Brien J, Kavanagh P. The syntheses of 1-(2-thienyl)-2-(methylamino) propane (methiopropamine) and its 3-thienyl isomer for use as reference standards. Drug Test Anal. 2013;5:145-149.
48. Schaeper J, Westphal F, Girreser U. Sicherstellung des Metamfetamin-Derivats Methiopropamin-Zusammenfassung der infrarotspektroskopischen, NMR-spektroskopischen und massenspektrometrischen Daten. Toxichem Krimtech. 2011;78:480-488.
49. Nelson DL, Lucaites VL, Wainscott DB, et al. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:1-6.
50. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131-181.
51. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897-3902.
52. Rickli A, Kopf S, Hoener MC, et al. Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol. 2015;172:3412-3425.
53. Stanczuk A, Morris N, Gardner EA, et al. Identification of (2-aminopropyl) benzofuran (APB) phenyl ring positional isomers in internet purchased products. Drug Test Anal. 2013;5:270-276.
54. Casale JF, Hays PA. The Characterization of 6-(2-Aminopropyl)benzofuran and Differentiation from its 4-, 5-, and 7-Positional Analogues. Microgram J. 2012;9:61-74.
55. Green AR, Nutt DJ. Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). J Psychopharmacol. 2014;28:711-718.
56. Dinger J, Meyer MR, Maurer HH. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett. 2014;230:28-35.
57. Dinger J, Meyer MR, Maurer HH. In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two cocktail approach. Arch Toxicol. 2014;DOI: 10.1007/s00204-014-1412-6 [Epub ahead of print].
58. Meyer MR, Wagmann L, Schneider-Daum N, et al. P-glycoprotein interactions of novel psychoactive substances-stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol. 2015;94:220-226.